Long-Term Outcome of Eltrombopag With First-Line Immunosuppressive Therapy for Newly Diagnosed Severe Aplastic Anemia.

Hirofumi YokotaKotaro MiyaoMasashi SawaSeitaro TerakuraShingo KurahashiYoshikazu IkomaNobuhiko ImahashiTakanobu MorishitaAkinao OkamotoTomohiro KajiguchiTakaaki OnoTomoko NaritaNobuhiro KanemuraKazutaka OzekiYumi KojimaKensuke NaitoKaori UchinoAkihiro TomitaHiroatsu IidaNaoto ImotoSenji KasaharaYuichiro InagakiTetsuya NishidaMakoto Murata

Published in: Journal of hematology (2024)

In summary, IST showed significantly better initial efficacy in the EPAG group. Although the addition of EPAG did not reduce the need for allo-SCT, no increase was observed in the incidence of CE with long-term EPAG use.

Keyphrases

newly diagnosed
chronic kidney disease
risk factors
iron deficiency
allogeneic hematopoietic stem cell transplantation
early onset
energy transfer
drug induced